Posted Date: 4/10/2017

Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase III Clinical Trial

Tetraphase Pharmaceuticals, Inc. recently announced completion of enrollment in IGNITE4, its ongoing Phase III clinical trial evaluating the efficacy and safety of intravenous (IV) eravacycline compared to meropenem in complicated intra-abdominal infections (cIAI). The company expects to report top-line data from this trial in the third quarter of 2017.

“Completing IGNITE4 enrollment ahead of schedule speaks to the strong investigator support for this study, along with the dedication and hard work by our internal team and collaborating clinical research organization,” said Guy Macdonald, President and CEO of Tetraphase. “Following the protocol-specified follow-up period, requisite data validation, and subsequent database lock activities, we now expect top-line data from IGNITE4 to be available during the third quarter of 2017. Assuming a positive outcome, we believe the data from IGNITE4, along with data from the successfully completed IGNITE1 trial, will form the basis of a US NDA filing for IV eravacycline in cIAI.”

Tetraphase also updated its guidance regarding the planned submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for IV eravacycline for the treatment of cIAI which will be supported by data from the IGNITE1 trial. The company expects to file the MAA during the third quarter of 2017.

“With respect to eravacycline in Europe, we are updating our prior guidance to reflect submission of a MAA to the EMA, the first regulatory filing for IV eravacycline as a potential new treatment for cIAI, also during the third quarter of 2017. We are well positioned to execute on these critical milestones with the goal of bringing eravacycline to the physicians and patients who need it,” Mr. Macdonald concluded.

IGNITE4 is a Phase III randomized, double-blind, double-dummy, multicenter, prospective study that is designed to assess the efficacy, safety, and pharmacokinetics of twice-daily eravacycline (1.0 mg/kg every 12 hours) compared with meropenem (1 g every 8 hours) for the treatment of cIAI.  The study is expected to enroll approximately 450 adult patients at 75 centers worldwide. The primary endpoint of IGNITE4 is clinical response at the test-of-cure (TOC) visit, which occurs 25 to 31 days after the initial dose of the study drug. The primary efficacy analysis will be conducted using a 12.5% non-inferiority margin in the microbiological intent-to-treat (micro-ITT) population.

Eravacycline is a novel, fully synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens that have been highlighted as urgent public health threats by both the World Health Organization and the US Centers for Disease Control (CDC).  Eravacycline has demonstrated potent activity against multidrug-resistant (MDR) pathogens, including carbapenem-resistant enterobacteriaceae (CRE), Acinetobacter baumannii, and colistin-resistant bacteria carrying the mcr-1 gene, and is being developed for the treatment of serious and life-threatening bacterial infections. Eravacycline is in Phase III clinical development for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

Eravacycline is currently being investigated in the company’s Phase III IGNITE (Investigating Gram-negative Infections Treated with Eravacycline) program. To date, eravacycline has been tested in over 1,300 patients and in two completed Phase III trials – IGNITE1 in patients with cIAI and IGNITE2 in patients with cUTI.  In IGNITE1, twice-daily IV eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem, was well tolerated, and achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates. The IGNITE1 data will support an MAA submission to the EMA for IV eravacycline for the treatment of patients with cIAI. Tetraphase is currently evaluating eravacycline in a second Phase III clinical trial in patients with cIAI (IGNITE4) comparing twice-daily IV eravacycline to meropenem. Assuming a positive outcome in IGNITE4, the company plans to use the results from IGNITE1 and IGNITE4 to support an NDA submission for IV eravacycline in cIAI. Tetraphase is also currently conducting IGNITE3, an additional Phase III trial evaluating once-daily IV eravacycline in patients with cUTI and, assuming a positive outcome, the company plans to use the results from IGNITE3 to support a supplemental NDA submission for eravacycline in cUTI.  In parallel, Tetraphase is continuing its efforts to develop an oral dose formulation of eravacycline. A Phase I clinical program is ongoing that is designed to evaluate and optimize the oral dosing regimen for eravacycline. For more information, visit

Related Taxonomy
This record has been viewed 1278 times.


Click here to see the showcases

BIO Investor Forum
October 17-18, 2017
The Westin St. Francis, San Francisco, CA US
Partnership Opportunities in Drug Delivery (PODD)
October 19-20
Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Vienna, Austria

November 12-17
San Diego, CA

Pre-Filled Syringes Europe
January 17-18, 2018
Copthorne Tara Hotel, London UK

Drug Delivery Partnerships
January 22-24 Palm Beach, FL

3rd Annual Drug Development Networking Summit
March 8, 2018  Hilton Hotel Parsippany NJ
PDA Annual Meeting
March 19-21 Orlando, FL
CPhI North America
April 24-26 Philadelphia, PA 
April 17-19 New York City
RDD (Respiratory Drug Delivery)
April 22-26 Tucson, AZ
BIO 2018
June 4-7 Boston, MA
Controlled Release Society Meeting
July 23-25 New York City
Universe of Prefilled Syringes & Injection Devices
October 8-9 Orlando, FL

Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions